… inflammatory diseases with upregulated levels of TNF-α, a number of therapeutic antibodies
… Despite their clinical success, the mode-of-action of different antibody formats with regard to …

… chimeric antibody and adalimumab a recombinant humanized IgG antibody against TNF-α. …
adalimumab in our study can be attributed to the mode of drug administration and regimen, …

… activity by anti-tumor necrosis factor (TNF)-agents leads to the development of anti-nuclear
antibodies … of publications deciphering the molecular and systemic interconnections of these …

… Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory … cytokines, and the expression of
adhesion molecules [1]. TNF-α … IFX is a monoclonal antibody to TNFα made up of a chimeric …

… Anti-tumour necrosis factor [anti-TNF] induced skin reactions are common adverse events
in paediatric inflammatory bowel disease [IBD]. We aimed to report on outcomes of children …

… anti-tumor necrosis factor-α … molecules for treating IBDs, conventional therapies including
5-aminosalicylates (5-ASA), corticosteroids, immunomodulators, and anti-tumor necrosis factor-…

… inflammation may be a triggering factor. We hypothesized that strong inflammation inhibitors
(eg, anti-tumor necrosis factor… and the possible modifications of many other molecules after …

… antibody Y9 with its assumed FcγR-dependent agonism and a PDL1 blocking antibody resulted
in superior anti-tumor activity… by FcγR-bound antibody molecules) is not fully clear in this …

… of inflammatory bowel diseases (IBD). Monoclonal antibodies against tumor necrosis factor
… small molecules and a new generation of antibodies which are more focused on the key …

… anti-tumor necrosis factor α agents have contributed to the development of new molecules
with different mechanisms of action … speed of onset of action: monoclonal antibodies that are …